FDA Expands Use of Multiple Cystic Fibrosis Medications
The full list of CFTR gene mutations for Trikafta, Symdeko and Kalydeco can be found in the updated prescribing information for each respective product.
The full list of CFTR gene mutations for Trikafta, Symdeko and Kalydeco can be found in the updated prescribing information for each respective product.
Vitamin D deficiency is associated with a higher risk of incident nontuberculous mycobacteria respiratory isolation in adults with cystic fibrosis.
Bronchitol is only indicated for use in adults who have passed the Bronchitol Tolerance Test.
Ivacaftor was safe and associated with improvements in cystic fibrosis transmembrane conductance regulator function in infants with CF and a gating mutation.
Intravenous antibiotics do not achieve greater sustained eradication of Pseudomonas aeruginosa in patients with cystic fibrosis compared with oral therapy.
The approval was based on data from a phase 3 open-label safety study that included a cohort of 6 children 4 months to <6 months of age.
Patients with cystic fibrosis who had pulmonary exacerbations treated with concomitant azithromycin and tobramycin had worse outcomes than those treated with tobramycin alone.
Age may influence outcomes in lung transplant recipients with cystic fibrosis.
Preliminary evidence suggests that the CFHealthHub criteria are valid and useful in diagnosing chronic Pseudomonas aeruginosa in adults with cystic fibrosis.
Patients with cystic fibrosis in Spain may have a lower incidence of COVID-19 as well as lower associated mortality compared with the general population.